Time to Load up on Atossa Shares? This Analyst Thinks So

TipRanks2021-06-15

The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（13）

yuxii
·2021-06-16
yes
Reply
Like
Report
Fold Replies
- BotakGuy:
  Ok
  2021-06-24
  Reply
  Report
lynjo
·2021-06-16
Hmm.
Reply
Like
Report
woanderful
·2021-06-15
The growth of the stocks aside, it is good news that there are developmemts in this area as breast cancer is more prevelant :(
Reply
Like
Report
J90
·2021-06-15
Cool
Reply
Like
Report
ELee2723
·2021-06-15
Hmm?
Reply
Like
Report
Maplewong714
·2021-06-15
[Smile] [Smile] [Smile] [Smile] [Smile] [Smile]
Reply
Like
Report
Skyfishhh
·2021-06-15
Hmmm
Reply
Like
Report
Hitrun
·2021-06-15
Go go go
Reply
4
Report
Fold Replies
- Sap:
  Like n comment pls
  2021-06-15
  Reply
  Report
- thekang:
  like and comment mine too
  2021-06-15
  Reply
  Report
sy0n
·2021-06-15
FOLLOW ME for DAILY LIKES for ALL YOUR MISSIONS!
Reply
5
Report
Fold Replies
- Sap:
  Like n commeny pls
  2021-06-15
  Reply
  Report
jowell
·2021-06-15
sick
Reply
2
Report
ProLim
·2021-06-15
Nice
Reply
Like
Report
PSFund
·2021-06-15
All in this stock!!!
Reply
3
Report
Fold Replies
- 投资不是一两天:
  lol
  2021-06-15
  Reply
  Report
- karen521818:
  wow
  2021-06-15
  Reply
  Report
Chong Yong
·2021-06-15
Great
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2143973689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-15 14:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2143973689","market":"us","top_or_hot":-1,"title":"Time to Load up on Atossa Shares? This Analyst Thinks So","media":"TipRanks","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Source Link</a>\n\n</div>\n","source":"lsy1606183248679","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TIME","symbol_name":"Clockwise Core Equity & Innovation ETF","start_time":0,"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","article_id":"2143973689","we_media_id":null,"thumbnails":[],"rights":{"source":"lsy1606183248679","url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","pubTimestamp":1623739755,"sourceInfo":{"source_id":"lsy1606183248679","name":"TipRanks"},"weMediaInfo":null,"summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TIME":"Clockwise Core Equity & Innovation ETF","ATOS":"Atossa Genetics Inc"},"translate_title":"是时候买Atossa的股票了？这位分析师是这么认为的","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":0.9,"TIME":0.9,"TWX":0.9},"content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":160116270,"gmtCreate":1623774622190,"gmtModify":1703819158988,"author":{"id":"3570443255970408","authorId":"3570443255970408","authorIdStr":"3570443255970408","name":"yuxii","avatar":"https://static.tigerbbs.com/72a96d0d673ad58e556302185ab1d594","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570443255970408"},"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/160116270","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4997186,"gmtCreate":1624543433893,"gmtModify":1663229922730,"authorId":3557831813182222,"author":{"id":3557831813182222,"authorId":3557831813182222,"name":"BotakGuy","avatar":"https://community-static.tradeup.com/news/022cac584c2e108f4c8bfef1e94aa79d","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.81%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":160116270,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":160329233,"gmtCreate":1623773068822,"gmtModify":1703819064394,"author":{"id":"3582677476432732","authorId":"3582677476432732","authorIdStr":"3582677476432732","name":"lynjo","avatar":"https://static.tigerbbs.com/2e27a74592895978b4a49574062e39e5","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582677476432732"},"htmlText":"Hmm.&nbsp;","listText":"Hmm.&nbsp;","text":"Hmm.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160329233","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187530288,"gmtCreate":1623758061844,"gmtModify":1703818307073,"author":{"id":"3583022959242714","authorId":"3583022959242714","authorIdStr":"3583022959242714","name":"woanderful","avatar":"https://static.tigerbbs.com/4e5b04b7e9dab6f7f58cb053028db83d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583022959242714"},"htmlText":"The growth of the stocks aside, it is good news that there are developmemts in this area as breast cancer is more prevelant :(","listText":"The growth of the stocks aside, it is good news that there are developmemts in this area as breast cancer is more prevelant :(","text":"The growth of the stocks aside, it is good news that there are developmemts in this area as breast cancer is more prevelant :(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187530288","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187614834,"gmtCreate":1623751985128,"gmtModify":1704210496673,"author":{"id":"3581487017513023","authorId":"3581487017513023","authorIdStr":"3581487017513023","name":"J90","avatar":"https://static.tigerbbs.com/59b9bd5153d367d5ee88324bdf6c6003","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581487017513023"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187614834","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187881532,"gmtCreate":1623749262426,"gmtModify":1704210365829,"author":{"id":"3576576038240682","authorId":"3576576038240682","authorIdStr":"3576576038240682","name":"ELee2723","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3576576038240682"},"htmlText":"Hmm?","listText":"Hmm?","text":"Hmm?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187881532","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187893778,"gmtCreate":1623748469794,"gmtModify":1704210323721,"author":{"id":"3581547759733110","authorId":"3581547759733110","authorIdStr":"3581547759733110","name":"Maplewong714","avatar":"https://static.tigerbbs.com/323fc7f3a981983f7fb4b6bc0ce1bbc5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581547759733110"},"htmlText":"[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;","listText":"[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;","text":"[Smile] [Smile] [Smile] [Smile] [Smile] [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187893778","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187802838,"gmtCreate":1623748315824,"gmtModify":1704210314568,"author":{"id":"3569705933447140","authorId":"3569705933447140","authorIdStr":"3569705933447140","name":"Skyfishhh","avatar":"https://static.tigerbbs.com/8005f30051fdf5124fa76cc65e36fc66","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3569705933447140"},"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187802838","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187366798,"gmtCreate":1623742091214,"gmtModify":1704210108433,"author":{"id":"3575868905564115","authorId":"3575868905564115","authorIdStr":"3575868905564115","name":"Hitrun","avatar":"https://static.tigerbbs.com/841cbf2a111833ec6efd1ed5a7f42dad","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575868905564115"},"htmlText":"Go go go","listText":"Go go go","text":"Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/187366798","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4766288,"gmtCreate":1623743725691,"gmtModify":1663228829834,"authorId":3559283513621894,"author":{"id":3559283513621894,"authorId":3559283513621894,"name":"Sap","avatar":"https://static.tigerbbs.com/2a00e2718679bd499f27764a78342e5c","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.44%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":187366798,"type":1,"supId":0,"prevId":0,"content":"Like n comment pls","text":"Like n comment pls","html":"Like n comment pls"},{"id":4767584,"gmtCreate":1623747257389,"gmtModify":1635320317817,"authorId":3579391473717940,"author":{"id":3579391473717940,"authorId":3579391473717940,"name":"thekang","avatar":"https://static.tigerbbs.com/257a55b2b4eff5b143f883be20deac55","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":187366798,"type":1,"supId":0,"prevId":0,"content":"like and comment mine <u>too</u>","text":"like and comment mine <u>too</u>","html":"like and comment mine <u>too</u>"}],"langContent":"EN"},{"id":187361216,"gmtCreate":1623741898935,"gmtModify":1704210105348,"author":{"id":"3581551145777728","authorId":"3581551145777728","authorIdStr":"3581551145777728","name":"sy0n","avatar":"https://static.tigerbbs.com/3e86d4ab414d26409f75886942c11698","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581551145777728"},"htmlText":"FOLLOW ME for DAILY LIKES for ALL YOUR MISSIONS!","listText":"FOLLOW ME for DAILY LIKES for ALL YOUR MISSIONS!","text":"FOLLOW ME for DAILY LIKES for ALL YOUR MISSIONS!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/187361216","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4766290,"gmtCreate":1623743735805,"gmtModify":1663228829448,"authorId":3559283513621894,"author":{"id":3559283513621894,"authorId":3559283513621894,"name":"Sap","avatar":"https://static.tigerbbs.com/2a00e2718679bd499f27764a78342e5c","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.44%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":187361216,"type":1,"supId":0,"prevId":0,"content":"Like n commeny pls","text":"Like n commeny pls","html":"Like n commeny pls"}],"langContent":"EN"},{"id":187387498,"gmtCreate":1623741670314,"gmtModify":1704210099662,"author":{"id":"3570418864419786","authorId":"3570418864419786","authorIdStr":"3570418864419786","name":"jowell","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570418864419786"},"htmlText":"sick","listText":"sick","text":"sick","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187387498","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187382995,"gmtCreate":1623741389317,"gmtModify":1704210094621,"author":{"id":"3572498650193459","authorId":"3572498650193459","authorIdStr":"3572498650193459","name":"ProLim","avatar":"https://static.tigerbbs.com/6eca4831f468b79e30513dff47109ae3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3572498650193459"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187382995","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187313255,"gmtCreate":1623740267677,"gmtModify":1704210074732,"author":{"id":"3581720614399200","authorId":"3581720614399200","authorIdStr":"3581720614399200","name":"PSFund","avatar":"https://static.tigerbbs.com/0ef339918e26708070f76eb849ca6534","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581720614399200"},"htmlText":"All in this stock!!!","listText":"All in this stock!!!","text":"All in this stock!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/187313255","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4765657,"gmtCreate":1623740436803,"gmtModify":1663228827233,"authorId":3576138559006730,"author":{"id":3576138559006730,"authorId":3576138559006730,"name":"投资不是一两天","avatar":"https://static.tigerbbs.com/36e77b5b6d744959b49fda03e290c69b","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":187313255,"type":1,"supId":4765654,"prevId":0,"content":"lol","text":"lol","html":"lol"},{"id":4765654,"gmtCreate":1623740420296,"gmtModify":1663228826939,"authorId":3586645063655275,"author":{"id":3586645063655275,"authorId":3586645063655275,"name":"karen521818","avatar":"https://static.tigerbbs.com/7d25d8609ba5fe3b8c704da13a47225e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":187313255,"type":1,"supId":0,"prevId":0,"content":"<u>wow</u>","text":"<u>wow</u>","html":"<u>wow</u>"}],"langContent":"EN"},{"id":187310326,"gmtCreate":1623740121065,"gmtModify":1704210071638,"author":{"id":"3574986309176499","authorId":"3574986309176499","authorIdStr":"3574986309176499","name":"Chong Yong","avatar":"https://static.tigerbbs.com/7a086f313ef69043ea3d4c14f102927b","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3574986309176499"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187310326","repostId":2143973689,"repostType":4,"repost":{"id":"2143973689","pubTimestamp":1623739755,"share":"https://ttm.financial/m/news/2143973689?lang=&edition=fundamental","pubTime":"2021-06-15 14:49","market":"us","language":"en","title":"Time to Load up on Atossa Shares? This Analyst Thinks So","url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","media":"TipRanks","summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc","TIME":"Clockwise Core Equity & Innovation ETF"},"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143973689","content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":24,"commentSize":13,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}